Gastroenterology

No Differences in Long-Term Drug Survival Between Biosimilar, Originator TNF Inhibitors

August 15th 2024

By Skylar Jeremias

An analysis of subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases found no significant differences in survival or discontinuation rates due to inefficacy or adverse events, with biosimilars showing lower overall discontinuation rates and higher retention rates.

Manitoba Adopts Biosimilar Switching Policy

August 7th 2024

By Skylar Jeremias

Article

Manitoba’s new policy means that all 10 Canadian provinces now have an initiative to boost biosimilar adoption and savings by transitioning patients on reference agents to biosimilar options.

Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline

August 3rd 2024

By Skylar Jeremias

Article

Products in line to face biosimilar competition are projected to increase their list prices in advance, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

CT-P13 Shows Similar Effectiveness, Safety in Biologic-Naive Patients With Crohn Disease

July 27th 2024

By Deana Ferreri, PhD

Article

Celltrion’s infliximab biosimilar CT-P13 demonstrates similar effectiveness and safety to the originator in biologic-naive patients with Crohn disease in a retrospective, real-world study in Japan.

Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval

July 24th 2024

By Skylar Jeremias

Article

Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.

Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction

July 20th 2024

By Deana Ferreri, PhD

Article

Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.

Samsung Bioepis’ Ustekinumab Biosimilar Demonstrates PK Equivalence in Healthy Adults

July 6th 2024

By Deana Ferreri, PhD

Article

A phase 1 study demonstrated pharmacokinetic (PK) bioequivalence of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the EU- and US-sourced reference products.

FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara

July 1st 2024

By Skylar Jeremias

Article

Pyzchiva (ustekinumab-ttwe) is the third ustekinumab biosimilar to receive approval for the American market. It was also approved with interchangeability.

Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD

June 29th 2024

By Deana Ferreri, PhD

Article

Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.

Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching

June 26th 2024

By Skylar Jeremias

Article

Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.